engineered-cytokines
(2)Sanuj Ravindran
Sanuj Ravindran, M.D., is the CEO of Simcha Therapeutics, a New Haven clinical-stage immunobiology company turning a once-overlooked immune molecule, interleukin-18, into a cancer weapon. A board-certified physician who spent a decade as a venture capitalist before becoming a serial biotech company-builder, Ravindran took the helm in 2022 to push ST-067, a decoy-resistant IL-18 designed to slip past the body's own off-switch and reawaken the immune system inside tumors. He has run drug programs across oncology and rare disease, structured more than $2 billion in deals, and bets his career on therapies that promise more than incremental gains.
Simcha Therapeutics
Simcha Therapeutics is a clinical-stage biopharmaceutical company in New Haven, Connecticut that uses directed evolution to engineer next-generation cytokine immunotherapies for cancer. Its lead program, ST-067, is a first-in-class 'decoy-resistant' interleukin-18 (IL-18) variant engineered to evade the natural decoy protein (IL-18BP) that tumors exploit to silence the immune system. Spun out of Aaron Ring's lab at Yale School of Medicine and backed by $40M in Series B financing, Simcha is advancing ST-067 through Phase 1/2 trials in solid tumors and partnering with Janssen to armor CAR T cell therapies.